AMRN
AMARIN CORP PLCUK
$13.93
+0.94%
$289.4M
No data for this timeframe.
Vol
Market Cap$289.4M
Cap SizeMicro Cap
Inst. Holders4 funds
Inst. Value$6.3M
Inst. Activity2 buys / 1 sells
SEC Reports3
Press Releases1
Recent Activity
Jun 4, 2026
SEC
The Supreme Court unanimously reversed the Federal Circuit, holding that Amarin failed to state a claim for induced infr
COURT-RULING — Impact 7/10
Jun 4, 2026
Event
Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
Court ruling from Supreme Court of the United States. Docket: 24-889
Apr 29, 2026
SEC
Amarin reported Q1 2026 revenue of $45.1M (+7% YoY), beating the $43.8M consensus, but GAAP EPS was -$0.03, a significan
8-K — Impact 4/10
Apr 29, 2026
earnings
Amarin Reports 2026 First Quarter Financial Results
<p align="center"><em>Total Revenue Increased Led by Higher International Sales</em></p>
Apr 18, 2026
Insider
Sterling Louis III sold 838 shares
Director @ $0.00 ($0.00)
Apr 18, 2026
Insider
Sterling Louis III sold 403 shares
Director @ $14.98 ($6.0K)
Apr 18, 2026
Insider
Sterling Louis III sold 838 shares
Director @ $0.00 ($0.00)
Feb 25, 2026
SEC
Amarin reported Q4 2025 financial results showing a 21% year-over-year decline in total net revenue to $49.2 million, dr
8-K — Impact 6/10
Price Targets
Historical data — last covering-analyst action Jun 2025. No current recommendation available.
$12.50 (Jun 2025)
Current $13.93
Low $12.00
Median $12.50
High $13.00
2 analysts
$12.00
$13.00
Analyst Ratings
0Strong Buy
0Buy
3Hold
2Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 25, 2025 | Goldman Sachs | MAINTAIN | Sell → Sell |
| Apr 17, 2025 | Goldman Sachs | MAINTAIN | Sell → Sell |
| Jun 20, 2024 | Cantor Fitzgerald | REITERATE | Overweight |
| Jun 18, 2024 | Cantor Fitzgerald | REITERATE | Overweight |
| Oct 25, 2023 | Jefferies | DOWNGRADE | Buy → Hold |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.10 ▼ -158.8% | $-0.10 — $-0.10 | -111% YoY | 1 |
| Next Q | $-0.01 ▼ -105.6% | $-0.01 — $-0.01 | -105% YoY | 1 |
| Current FY | $-0.01 ▼ -101.3% | $-0.01 — $-0.01 | -125% YoY | 1 |
| Next FY | $0.98 ▼ -16.2% | $0.98 — $0.98 | 9900% YoY | 1 |
Latest Reports
BEARISH
COURT-RULING
7/10
The Supreme Court unanimously reversed the Federal Circuit, holding that Amarin failed to state a claim for induced infr
Jun 4, 2026
NEUTRAL
8-K
4/10
Amarin reported Q1 2026 revenue of $45.1M (+7% YoY), beating the $43.8M consensus, but GAAP EPS was -$0.03, a significan
Apr 29, 2026
NEUTRAL
Press
4/10
Amarin Corporation announced that additional subgroup and mechanistic data from the REDUCE-IT trial will be presented at
Mar 16, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $4.6M | ADD |
| TWO SIGMA INVESTMENTS, LP | $1.6M | ADD |
| WELLS FARGO & COMPANY/MN | $129.1K | ADD |
| BANK OF AMERICA CORP | $6.0K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 18, 2026 | Sterling Louis | M | $0.00 |
| Apr 18, 2026 | Sterling Louis | F | $6.0K |
| Apr 18, 2026 | Sterling Louis | M | $0.00 |
| Apr 18, 2026 | Sullivan Diane | M | $0.00 |
| Apr 18, 2026 | Sullivan Diane | F | $6.0K |
4 institutional holders with $6.3M total value (450,961 shares) as of 2025-Q4. Top holders: MORGAN, TWO, WELLS. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 330,109 | $4.6M | 73.2% | ADD +65.5% |
| 2 | TWO SIGMA INVESTMENTS, LP | 111,168 | $1.6M | 24.7% | ADD +85.1% |
| 3 | WELLS FARGO & COMPANY/MN | 9,254 | $129.1K | 2.1% | ADD +34.8% |
| 4 | BANK OF AMERICA CORP /DE/ | 430 | $6.0K | 0.1% | TRIM -71.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | ADD | 60,071 | 111,168 | +85.1% | $1.6M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 6,864 | 9,254 | +34.8% | $129.1K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,527 | 430 | -71.8% | $6.0K | 2025-Q4 |
| MORGAN STANLEY | ADD | 162,966 | 269,663 | +65.5% | $4.4M | 2025-Q3 |
| UBS Group AG | DOUBLED | 6,091 | 16,289 | +167.4% | $266.8K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 2,674 | 6,864 | +156.7% | $112.4K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 16,048 | 1,527 | -90.5% | $25.0K | 2025-Q3 |
| MORGAN STANLEY | NEW | — | 162,966 | — | $2.6M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 59,024 | — | $957.4K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEW | — | 16,048 | — | $260.3K | 2025-Q2 |
| UBS Group AG | NEW | — | 6,091 | — | $98.8K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEW | — | 2,674 | — | $43.4K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | EXIT | 51,667 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | EXIT | 338,431 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MORGAN STANLEY | EXIT | 2,621,963 | 0 | -100.0% | $0.00 | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 1,855,933 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MORGAN STANLEY | TRIM | 4,406,422 | 2,621,963 | -40.5% | $1.2M | 2025-Q1 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 343,594 | 82,100 | -76.1% | $36.8K | 2025-Q1 |
| MORGAN STANLEY | ADD | 2,545,752 | 4,406,422 | +73.1% | $2.1M | 2024-Q4 |
| UBS Group AG | TRIM | 658,326 | 354,561 | -46.1% | $172.0K | 2024-Q4 |
12 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 18, 2026 | Sterling Louis III | Director | M | 838 | $0.00 | $0.00 |
| Apr 18, 2026 | Sterling Louis III | Director | F | 403 | $14.98 | $6.0K |
| Apr 18, 2026 | Sterling Louis III | Director | M | 838 | $0.00 | $0.00 |
| Apr 18, 2026 | Sullivan Diane E. | Director | M | 838 | $0.00 | $0.00 |
| Apr 18, 2026 | Sullivan Diane E. | Director | F | 403 | $14.98 | $6.0K |
| Apr 18, 2026 | Sullivan Diane E. | Director | M | 838 | $0.00 | $0.00 |
| Apr 18, 2026 | O'Connor Oliver | Director | F | 438 | $14.98 | $6.6K |
| Apr 18, 2026 | Cohen Paul | Director | M | 838 | $0.00 | $0.00 |
| Apr 18, 2026 | Odysseas Kostas D | Director | M | 838 | $0.00 | $0.00 |
| Apr 18, 2026 | Odysseas Kostas D | Director | F | 403 | $14.98 | $6.0K |
| Apr 18, 2026 | Odysseas Kostas D | Director | M | 838 | $0.00 | $0.00 |
| Apr 18, 2026 | Horn Keith | Director | M | 838 | $0.00 | $0.00 |
| Apr 18, 2026 | Horn Keith | Director | F | 403 | $14.98 | $6.0K |
| Apr 18, 2026 | Horn Keith | Director | M | 838 | $0.00 | $0.00 |
| Apr 18, 2026 | O'Connor Oliver | Director | M | 838 | $0.00 | $0.00 |
| Apr 18, 2026 | O'Connor Oliver | Director | M | 838 | $0.00 | $0.00 |
| Apr 18, 2026 | Cohen Paul | Director | M | 838 | $0.00 | $0.00 |
| Apr 18, 2026 | Cohen Paul | Director | F | 403 | $14.98 | $6.0K |
| Apr 18, 2026 | Bonfiglio Patrice Eadon | Director | M | 838 | $0.00 | $0.00 |
| Apr 18, 2026 | Bonfiglio Patrice Eadon | Director | F | 403 | $14.98 | $6.0K |
| Apr 18, 2026 | Bonfiglio Patrice Eadon | Director | M | 838 | $0.00 | $0.00 |
| Apr 1, 2026 | Fishman Peter L. | SVP, CFO | M | 125 | $0.00 | $0.00 |
| Apr 1, 2026 | Fishman Peter L. | SVP, CFO | F | 62 | $14.46 | $896.52 |
| Apr 1, 2026 | Fishman Peter L. | SVP, CFO | M | 125 | $0.00 | $0.00 |
| Feb 1, 2026 | Provoost Jonathan | EVP, Chief Legal Officer | A | 8,013 | $0.00 | $0.00 |
| Feb 1, 2026 | Provoost Jonathan | EVP, Chief Legal Officer | A | 36,060 | $0.00 | $0.00 |
| Feb 1, 2026 | Ketchum Steven B | EVP, Chief Scientific Officer | A | 8,013 | $0.00 | $0.00 |
| Feb 1, 2026 | Ketchum Steven B | EVP, Chief Scientific Officer | A | 36,060 | $0.00 | $0.00 |
| Feb 1, 2026 | Fishman Peter L. | SVP, CFO | A | 6,167 | $0.00 | $0.00 |
| Feb 1, 2026 | Fishman Peter L. | SVP, CFO | A | 27,750 | $0.00 | $0.00 |
| Feb 1, 2026 | Keenan David Paul | EVP, Chief Operating Officer | A | 8,013 | $0.00 | $0.00 |
| Feb 1, 2026 | Keenan David Paul | EVP, Chief Operating Officer | A | 30,060 | $0.00 | $0.00 |
| Feb 1, 2026 | Berg Aaron | President and CEO | A | 26,793 | $0.00 | $0.00 |
| Feb 1, 2026 | Berg Aaron | President and CEO | A | 120,566 | $0.00 | $0.00 |
| Jan 31, 2026 | Ketchum Steven B | EVP, Chief Scientific Officer | M | 2,246 | $0.00 | $0.00 |
| Jan 31, 2026 | Ketchum Steven B | EVP, Chief Scientific Officer | F | 1,235 | $15.42 | $19.0K |
| Jan 31, 2026 | Ketchum Steven B | EVP, Chief Scientific Officer | M | 2,246 | $0.00 | $0.00 |
| Jan 31, 2026 | Fishman Peter L. | SVP, CFO | M | 563 | $0.00 | $0.00 |
| Jan 31, 2026 | Fishman Peter L. | SVP, CFO | F | 310 | $15.42 | $4.8K |
| Jan 31, 2026 | Fishman Peter L. | SVP, CFO | M | 563 | $0.00 | $0.00 |
| Jan 31, 2026 | Keenan David Paul | EVP, Chief Operating Officer | M | 2,246 | $0.00 | $0.00 |
| Jan 31, 2026 | Keenan David Paul | EVP, Chief Operating Officer | F | 1,173 | $15.42 | $18.1K |
| Jan 31, 2026 | Keenan David Paul | EVP, Chief Operating Officer | M | 2,246 | $0.00 | $0.00 |
| Jan 31, 2026 | Berg Aaron | President and CEO | M | 2,246 | $0.00 | $0.00 |
| Jan 31, 2026 | Berg Aaron | President and CEO | F | 1,235 | $15.42 | $19.0K |
| Jan 31, 2026 | Berg Aaron | President and CEO | M | 2,246 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 5.7/10.
BEARISH
COURT-RULING
7/10
The Supreme Court unanimously reversed the Federal Circuit, holding that Amarin failed to state a cl
Jun 4, 2026
NEUTRAL
8-K
4/10
Amarin reported Q1 2026 revenue of $45.1M (+7% YoY), beating the $43.8M consensus, but GAAP EPS was
Apr 29, 2026
BEARISH
8-K
6/10
Amarin reported Q4 2025 financial results showing a 21% year-over-year decline in total net revenue
Feb 25, 2026
Historical analyst distribution (last covering-analyst action Jun 2025): 0% buy across 7 analysts — 0 strong buy, 0 buy, 3 hold, 2 sell, 2 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jun 2025. No current recommendation available.
$12.50 mean target (Jun 2025)
$12.00 Low
$13.00 High
| Metric | Value |
|---|---|
| Current Price | $13.93 |
| Target Low | $12.00 |
| Target Mean | $12.50 |
| Target Median | $12.50 |
| Target High | $13.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.10 | $-0.10 | $-0.10 | -111.5% | -158.8% | — | $0.0B | -38.9% | 1 |
| Next Q 2026-09-30 |
$-0.01 | $-0.01 | $-0.01 | -105.3% | -105.6% | — | $0.0B | -11.1% | 1 |
| Current FY 2026-12-31 |
$-0.01 | $-0.01 | $-0.01 | -125.0% | -101.3% | 1↑ 0↓ | $0.2B | -14.7% | 1 |
| Next FY 2027-12-31 |
$0.98 | $0.98 | $0.98 | 9900.0% | -16.2% | 1↑ 0↓ | $0.2B | 5.9% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.100 | |
| 7d ago | $0.170 | -0.270 |
| 30d ago | $0.170 | -0.270 |
| 60d ago | $0.000 | -0.100 |
| 90d ago | $0.000 | -0.100 |
14 analyst firms have rated this stock: 6 upgrades, 10 downgrades, 12 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 25, 2025 | Goldman Sachs | MAINTAIN | Sell | Sell |
| Apr 17, 2025 | Goldman Sachs | MAINTAIN | Sell | Sell |
| Jun 20, 2024 | Cantor Fitzgerald | REITERATE | — | Overweight |
| Jun 18, 2024 | Cantor Fitzgerald | REITERATE | — | Overweight |
| Oct 25, 2023 | Jefferies | DOWNGRADE | Buy | Hold |
| Jul 20, 2023 | Goldman Sachs | MAINTAIN | Sell | Sell |
| Jul 19, 2023 | Northland Capital Markets | MAINTAIN | Market Perform | Market Perform |
| Jan 6, 2023 | Jefferies | UPGRADE | Hold | Buy |
| Oct 19, 2022 | SVB Leerink | MAINTAIN | — | Market Perform |
| May 24, 2022 | Goldman Sachs | MAINTAIN | — | Sell |
| May 6, 2022 | JP Morgan | DOWNGRADE | Neutral | Underweight |
| May 5, 2022 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| May 5, 2022 | SVB Leerink | DOWNGRADE | Outperform | Market Perform |
| Feb 16, 2022 | SVB Leerink | MAINTAIN | — | Outperform |
| Jan 31, 2022 | SVB Leerink | MAINTAIN | — | Outperform |
| Sep 9, 2021 | SVB Leerink | INITIATE | — | Outperform |
| May 12, 2021 | Goldman Sachs | DOWNGRADE | Neutral | Sell |
| Feb 1, 2021 | SVB Leerink | MAINTAIN | — | Outperform |
| Sep 28, 2020 | SVB Leerink | MAINTAIN | — | Outperform |
| Aug 26, 2020 | Piper Sandler | INITIATE | — | Overweight |
| May 4, 2020 | Aegis Capital | MAINTAIN | — | Buy |
| May 4, 2020 | SVB Leerink | MAINTAIN | — | Outperform |
| Apr 1, 2020 | Citigroup | MAINTAIN | — | Buy |
| Mar 31, 2020 | Stifel | MAINTAIN | — | Hold |
| Mar 31, 2020 | Oppenheimer | UPGRADE | Underperform | Perform |
| Mar 31, 2020 | Goldman Sachs | DOWNGRADE | Buy | Neutral |
| Mar 31, 2020 | Jefferies | DOWNGRADE | Buy | Hold |
| Mar 13, 2020 | Goldman Sachs | UPGRADE | Neutral | Buy |
| Mar 2, 2020 | Cowen & Co. | INITIATE | — | Outperform |
| Feb 26, 2020 | Oppenheimer | MAINTAIN | — | Underperform |
| Feb 18, 2020 | Citigroup | UPGRADE | Neutral | Buy |
| Jan 6, 2020 | JP Morgan | INITIATE | — | Neutral |
| Dec 16, 2019 | Oppenheimer | MAINTAIN | — | Underperform |
| Dec 16, 2019 | Stifel | DOWNGRADE | Buy | Hold |
| Nov 20, 2019 | Oppenheimer | INITIATE | — | Underperform |
| Nov 18, 2019 | Citigroup | DOWNGRADE | Buy | Neutral |
| Oct 31, 2019 | Aegis Capital | INITIATE | — | Buy |
| Oct 15, 2019 | Goldman Sachs | INITIATE | — | Neutral |
| Mar 22, 2019 | Stifel | INITIATE | — | Buy |
| Nov 2, 2018 | Citigroup | DOWNGRADE | Buy | Neutral |
| Oct 17, 2018 | Citigroup | MAINTAIN | Buy | Buy |
| Sep 25, 2018 | Jefferies | MAINTAIN | Buy | Buy |
| Sep 25, 2018 | Citigroup | MAINTAIN | Buy | Buy |
| Oct 19, 2016 | Citigroup | INITIATE | — | Buy |
| Oct 5, 2016 | Cantor Fitzgerald | INITIATE | — | Buy |
| Oct 4, 2016 | Cantor Fitzgerald | INITIATE | — | Buy |
| May 12, 2016 | Jefferies | INITIATE | — | Buy |
| Mar 12, 2015 | HC Wainwright & Co. | UPGRADE | — | Buy |
| Feb 18, 2015 | SunTrust Robinson Humphrey | UPGRADE | Neutral | Buy |
| Nov 10, 2014 | Citigroup | MAINTAIN | — | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 3 | 2 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 3 | 2 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 3 | 2 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 3 | 2 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 3 | 2 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 3 | 2 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
Enforcement
Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
Court ruling from Supreme Court of the United States. Docket: 24-889
Apr 29, 2026
earnings
Amarin Reports 2026 First Quarter Financial Results
<p align="center"><em>Total Revenue Increased Led by Higher International Sales</em></p>
Apr 29, 2026
earnings_calendar
AMRN Q1 2026 Earnings Scheduled — 2026-04-29
Apr 8, 2026
other
American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction
<p align="justify">DUBLIN and BRIDGEWATER, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin”), a company comm
Mar 16, 2026
fda
New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
<p align="justify">DUBLIN and BRIDGEWATER, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to ad
Feb 25, 2026
earnings_calendar
AMRN Q4 2025 Earnings Before Market Open — 2026-02-25